HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.

ABSTRACT: Human sulfatase‑1 (HSulf‑1) is emerging as a novel prognostic biomarker in breast cancer. Previous studies demonstrated HSulf‑1 to function as a negative regulator of cyclin D1 in breast cancer. Accumulating preclinical evidence is supporting the efficacy of cyclin‑dependent kinase (CDK) 4/6 inhibitors against the luminal androgen receptor sub‑type of triple‑negative breast cancer (TNBC). It was therefore hypothesized that HSulf‑1 may cooperate with CDK4/6 inhibitors to control cell cycle progression in breast cancer cells. HSulf‑1 expression was found to be downregulated in TNBC tissues and cell lines compared with that in healthy tissues and non‑breast cancer cell lines, respectively. High levels of HSulf‑1 expression was also found to be associated with increased progression‑free surviv

SUBMITTER: Chen F 

PROVIDER: S-EPMC7252455 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature